Japan Society of Obstetrics and Gynecology and Japan Society for Menopause and Women's Health 2017 guidelines for hormone replacement therapy

Okano, Hiroya; Higuchi, Tsuyoshi; Kurabayashi, Takumi; Makita, Kazuya; Mizunuma, Hideki; Mochizuki, Yuji; Obayashi, Shigeru; Takamatsu, Kiyoshi

doi:10.1111/jog.13684

Cited by 16 publications

(34 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…23 In contrast, insurance coverage for the use of estrogen preparations for treatment of osteoporosis is limited in Japan, although the use of estrogen preparations for menopausal symptoms and estrogendeficiency symptoms is covered by insurance. 24 The duration of HRT use is an important determinant of its prevalence. The prevalence of HRT use determined in a crosssectional study may be similar to that in a long-term longitudinal study if the duration of HRT use is long.…”

Section: Discussionmentioning

confidence: 99%

Prevalence of the Use of Oral Contraceptives and Hormone Replacement Therapy in Japan: The Japan Nurses’ Health Study

Ideno

Shinozaki

Kitahara

et al. 2022

Journal of Epidemiology

Self Cite

View full text Add to dashboard Cite

Background: There have been few community-based epidemiological studies in which the prevalence of exogenous hormone use, including the use of oral contraceptives (OCs) and hormone replacement therapy (HRT), has been accurately assessed in Japan. Methods: We have been conducting repeated surveys of participants in the Japan Nurses' Health Study (JNHS), as a nationwide prospective cohort study, since 2001. We determined the prevalence of exogenous hormone use at baseline and during a 10-year follow-up period. A total of 15,019 female nurses participated in the JNHS follow-up cohort. We determined the prevalence of OC use in 14,839 women <60 years of age at baseline and the prevalence of HRT use in 7,915 women, excluding premenopausal women, at the last time they answered a questionnaire. The duration of HRT use was estimated using the Kaplan-Meier method. Results: Six percent of the participants used OCs. The proportion of HRT users who stopped HRT before the baseline survey, the proportion of women using HRT during the follow-up period, and the proportion of all of the participants who had used HRT were 3.2%, 10.6%, and 13.8%, respectively. The median duration of HRT use was 2 years. Conclusions: The lifetime prevalences of exogenous hormone use during this prospective study conducted in Japanese nurses were 6.0% for OCs and 13.8% for HRT. The information obtained in this study will be useful for clarification of the association between exogenous estrogen exposure and estrogen-related diseases as future research.

show abstract

Section: Discussionmentioning

confidence: 99%

Prevalence of the Use of Oral Contraceptives and Hormone Replacement Therapy in Japan: The Japan Nurses’ Health Study

Ideno

Shinozaki

Kitahara

et al. 2022

Journal of Epidemiology

Self Cite

View full text Add to dashboard Cite

show abstract

“…[ 6 ] Therefore, prior to administration, risk assessment of HRT such as the presence of complications or existing medical conditions should be performed. [ 7 ]…”

Section: Discussionmentioning

confidence: 99%

Postmenopausal pregnancy: A case report

Mirsafi

Attarha

2020

Iranian J Nursing Midwifery Res

View full text Add to dashboard Cite

Abnormal vaginal bleeding is one of the complaints of women during menopause. Various diseases such as endometrial atrophy, polyps, and endometrial cancers may lead to postmenopausal vaginal bleeding. This report describes a case of postmenopausal vaginal bleeding caused by pregnancy. A 54-year-old woman referred to the prenatal clinic in Arak, Iran, with postmenopausal vaginal bleeding in 2018. Transabdominal ultrasound revealed an uterine pregnancy. At 28 weeks of gestation, she referred to the health center and her prenatal care began in the midwifery clinic. She gave birth to a baby girl at 34 weeks through a cesarian section. This case reminds practitioners and midwives that pregnancy may be one of the etiologies of postmenopausal vaginal bleeding especially in women with sexual activity. Therefore, a free beta-subunit human chorionic gonadotropin (HCG) hormone measurement should be conducted and if found to be elevated, followed by appropriate imaging tests.

show abstract

“…Despite HT being the most effective available treatment for VMS, only 3-10% of affected women in the US and Europe use HT, in part due to the safety concerns of stroke, breast cancer, coronary heart disease, and other illnesses as identified by the Women's Health Initiative (WHI) [67], and corroborated in recent clinical reports [17,68,73,74]. Although current guidelines recommend HT as first-line treatment, particularly for symptomatic women <60 years of age or within 10 years of menopause [13][14][15][16], many women cannot take HT due to safety and tolerability concerns driven by medical history or concomitant medical conditions, or make an informed decision to not take it.…”

Section: Expert Opinionmentioning

confidence: 99%

“…The standard of care for VMS associated with menopause is hormone therapy (HT) with combined estrogen and progesterone, or estrogen alone [12]. Although international clinical practice guidelines recognize a continued role for HT, particularly for symptomatic women <60 years of age or within 10 years of menopause [13][14][15][16], safety and tolerability concerns have discouraged HT use due to a potential increased risk of hormone-dependent cancers (such as breast cancer) [17], and a measured increased risk of stroke and venous thromboembolism [13,18]. HT should therefore only be prescribed with regular monitoring and assessment [15,[19][20][21].…”

Section: Introductionmentioning

confidence: 99%

Fezolinetant in the treatment of vasomotor symptoms associated with menopause

Depypere

Lademacher

Siddiqui

et al. 2021

Expert Opinion on Investigational Drugs

View full text Add to dashboard Cite

Introduction: Although international clinical practice guidelines recognize a continued role for menopausal hormone therapy (HT), particularly for symptomatic women <60 years of age or within 10 years of menopause, safety and tolerability concerns have discouraged HT use due to potential links with a perceived increased risk of hormone-dependent cancers, and an established risk of stroke and venous thromboembolism. There is therefore a need for safe, effective non-hormonal therapy for relief of menopausal vasomotor symptoms (VMS).Areas covered: This narrative review summarizes the dataset accrued for fezolinetant, a neurokinin-3 receptor (NK3R) antagonist in clinical development for menopause-associated VMS. Expert opinion: Altered signaling in neuroendocrine circuits at menopause leads to VMS wherein NK3R activity plays a key role to modulate the thermoregulatory center in a manner conducive to triggering the 'hot flash' response. Thus, a new generation of NK3R antagonists has entered clinical development to specifically target the mechanistic basis of VMS. Fezolinetant is the most advanced NK3R antagonist in terms of stage of clinical development. Results to date have demonstrated rapid and substantial reduction in VMS frequency and severity and associated improvements in health-related quality of life. NK3R antagonists offer a non-hormonal alternative to HT for the treatment of menopause-related VMS.

show abstract

Japan Society of Obstetrics and Gynecology and Japan Society for Menopause and Women's Health 2017 guidelines for hormone replacement therapy

Cited by 16 publications

References 0 publications

Prevalence of the Use of Oral Contraceptives and Hormone Replacement Therapy in Japan: The Japan Nurses’ Health Study

Prevalence of the Use of Oral Contraceptives and Hormone Replacement Therapy in Japan: The Japan Nurses’ Health Study

Postmenopausal pregnancy: A case report

Fezolinetant in the treatment of vasomotor symptoms associated with menopause

Contact Info

Product

Resources

About